| Q83388958 | A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis |
| Q37840260 | Acute myeloid leukaemia in the elderly: a review |
| Q48133412 | Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome. |
| Q36579065 | Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research |
| Q36850764 | Blood and marrow transplantation in elderly acute myeloid leukaemia patients - older certainly is not better |
| Q39002065 | Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis |
| Q33813439 | Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome |
| Q45402377 | Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders |
| Q61873063 | Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies |
| Q46724769 | Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation |
| Q53210874 | Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia. |
| Q38405625 | Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. |
| Q44889315 | Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCT. |
| Q38010596 | Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis. |
| Q37810969 | Older patients with acute myeloid leukemia |
| Q36723291 | Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. |
| Q36548370 | Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct |
| Q33838116 | Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age |
| Q36007719 | Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning |
| Q85157580 | Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT |
| Q39192183 | Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. |
| Q37404489 | The evolution of hematopoietic SCT in myelodysplastic syndrome |
| Q83322806 | Unrelated cord blood allogeneic stem cell transplantation for MDS |